Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2018 / Cilt: 24 - Sayı: 6

Availability, Use and Development of Animal Models for the Assessment of Drug-Drug Interactions and Safety of Direct Oral Anticoagulants

Yeni Nesil Oral Antikoagulanların İlaç İlaç Etkileşimleri ve Güvenliliğinin Değerlendirilebilmesi İçin Hayvan Modellerinin Geliştirilmesi, Kullanımı ve Bulunabilirliği

Pages
917–923
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The focus of this review will be the availability, use and development of animalmodels to assess drug drug interactions and safety profile of DOACs.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Direct oral anticoagulants (DOACs) are novel, direct acting drugs that are selective for either thrombin or activated factor X.
📊
Key Findings & Data:Due to theirobvious benefits for patients (broader therapeutic window, are not routinely monitored etc.), they are increasingly used as an alternativeto vitamin K antagonists.
💡
Conclusion & Impact:The focus of this review will be the availability, use and development of animalmodels to assess drug drug interactions and safety profile of DOACs.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Direct oral anticoagulants (DOACs) are novel, direct acting drugs that are selective for either thrombin or activated factor X. Due to theirobvious benefits for patients (broader therapeutic window, are not routinely monitored etc.), they are increasingly used as an alternativeto vitamin K antagonists. One of the major indications for the use of DOACs is the stroke prevention in patients with atrial fibrillation (AF).Although, the DOAC use becomes extensive in the clinical area especially cardiology, many drug drug interactions occur when DOACs areused with other drugs. Also, the safety profile of DOACs is still to be investigated. Animal models can be used to investigate the drug druginteractions and safety of DOACs under standart laboratory conditions. Unfortunately, there is not sufficient data that investigates the drugdrug interactions and safety of DOACs in animal models. The focus of this review will be the availability, use and development of animalmodels to assess drug drug interactions and safety profile of DOACs.

Özet

Direkt oral antikoagulanlar (DOAK’lar), yeni, thrombine veya aktive faktör Xa’ya selektif olan direkt etkili ilaçlardır. Bu yeni oral antikoagulan ilaçların, klasik antikoagulan ilaçlara göre hastalar açısından çok sayıda avantajları vardır (izleme ihtiyacının olmaması, geniş tedavi penceresi vbg.). Yakın geçmişte, direkt oral antikoagulanlar, tromboembolizmi önleme ve tedavisinde K vitamini antagonistlerine alternatif olarak sunulmuşlardır. DOAKların ana kullanım alanı, atrial fibrilasyonlu hastalarda inmenin önlenmesidir. Ancak, öte yandan, DOAK’ların diğer ilaçlar ile kombine kullanımı sırasında ilaç-ilaç etkileşimleri oluşabilmekte ve güvenlilik profilleri henüz yeterli düzeyde bilinmemektedir. Günümüzde, DOAK’ların ilaç-ilaç etkileşimi ve güvenliliğini araştırmada kullanılan hayvan modelleri henüz yeterli değildir. Bu derlemenin amacı, DOAK’ların ilaç-ilaç etkileşimi ve güvenliliğini araştıran hayvan modellerinin daha da geliştirilmesi, kullanımı ve bulunabilirliğidir.

🔖

Cite This Article

ÇELİKYURT, İ. K. (2022). Availability, Use and Development of Animal Models for the Assessment of Drug-Drug Interactions and Safety of Direct Oral Anticoagulants. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 24 - Sayı: 6, 917–923. https://ajindex.com/articles/569821

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Shih AW, Crowther MA: Reversal of direct oral anticoagulants: A practical approach. Hematology Am Soc Hematol Educ Program, 2016 (1): 612-619, 2016. DOI:10.1182/asheducation-2016.1.612 Vargas M, Marra A, Perrone A, Servillo G: Bleeding management in patients with new oral anticoagulants. Minerva Anestesiol, 82 (8): 884- 894, 2016.
  2. Proietti M, Lip GYH: Antidotes to non-vitamin K oral anticoagulants: Necessary or not? Expert Opin Pharmacother, 16 (11): 1573-1576, 2015. DOI: 10.1517/14656566.2015.1057119 Hu TY, Vaidya VR, Asirvatham SJ: Reversing anticoagulant effects of novel oral anticoagulants: Role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag, 12, 35-44, 2016. DOI: 10.2147/ VHRM.S89130 Pollack CV Jr, Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, Kam CW, Kleine E, Levy JH, Sellke FW, Steiner T, Ustyugova A, Weitz JI: Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ, 20 (5): 435-442, 2017. DOI: 10.1080/13696998.2016.1273229 Rahmat NA, Lip GYH: Monitoring the effects and antidotes of the non-vitamin K oral anticoagulants. Arrhythm Electrophysiol Rev, 4 (1): 90- 95, 2015. DOI: 10.15420/aer.2015.04.02.90 Reddy ST, Cossey TC, Savitz SI, Grotta JC: Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep, 17 (9): 67, 2017. DOI: 10.1007/s11910-017-0774-6 Ansell JE: Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis, 41 (2): 248-252, 2016. DOI: 10.1007/s11239-015-1288-1
  3. Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, Koren G: Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol, 123, 1256-1261, 2014. DOI: 10.1097/AOG.0000000000000277 Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézay O, Bertoletti L, Delavenne X: In vitro assessment of pharmacokinetic drug drug ınteractions of direct oral anticoagulants: Type 5-phosphodiesterase ınhibitors are ınhibitors of rivaroxaban and apixaban efflux by P-glycoprotein. J Pharmacol Exp Ther, 365 (3): 519-525, 2018. DOI: 10.1124/jpet.117.245993 Gacar N, Gocmez S, Utkan T, Gacar G, Komsuoglu I, Tugay M, Utkan NZ: Effects of resveratrol on ileal smooth muscle reactivity in polymicrobial sepsis model. J Surg Res, 174 (2): 339-343, 2012